Peripheral blood stem cell transplantation in the treatment of progressive multiple sclerosis: First results of a pilot study

Bone Marrow Transplantation

Volumn 20, Issue 8, 1997, Pages 631-638

  Fassas, A ^a   Anagnostopoulos, A ^a   Kazis, A ^a   Kapinas, K ^a   Sakellari, I ^a   Kimiskidis, V ^a   Tsompanakou, A ^a  

^a G PAPANICOLAOU HOSPITAL   (Greece)

Author keywords

Haematopoietic stem cell transplantation; Multiple sclerosis

Indexed keywords

CYCLOPHOSPHAMIDE; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOSUPPRESSIVE AGENT; THYMOCYTE ANTIBODY;

ADULT; ARTICLE; BEAM THERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG HYPERSENSITIVITY; FEMALE; HUMAN; MALE; MULTIPLE SCLEROSIS; NEUROTOXICITY; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION;

EID: 0030714110     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1700944     Document Type: Article

References (50)

1. Poser CM. Notes on the pathogenesis of multiple sclerosis. Clin Neurosci 1994; 2: 258-265.
2. Matthews WB. Course and prognosis. In: Matthews WB, Compston A, Allen IV, Martyn CN (eds). McAlpine's Multiple Sclerosis, 2nd edn. Churchill Livingstone: Singapore 1991, pp 139-163.
3. Gulcher JR, Vartanian T, Stefansson K. Is multiple sclerosis an autoimmune disease? Clin Neurosci 1994; 2: 246-252.
4. van Oosten BW, Truyen L, Barkhof F, Polman CH. Multiple sclerosis therapy: a practical guide. Drugs 1995; 49: 200-212.
5. Cook SD, Devereux C, Troiano R et al. Effect of total lymphoid irradiation in chronic progressive multiple sclerosis. Lancet 1996; i: 1405-1409.
6. Hauser SL, Dawson DM, Lehrich JR et al. Intensive immunosuppression in progressive multiple sclerosis. New Engl J Med 1983; 308: 173-180.
7. Likosky WH, Fireman B, Elmore R et al. Intense immunosuppression in chronic progressive multiple sclerosis: the Kaiser study. J Neurol Neurosurg Psychiatr 1991; 54: 1055-1060.
8. The Canadian Cooperative Multiple Sclerosis Study Group. The Canadian cooperative trial of cyclophosphamide and plasma exchange in progressive multiple sclerosis. Lancet 1991; 337: 441-446.
9. Weiner HL, Mackin GA, Orav EJ et al. Intermittent cyclophosphamide pulse therapy in progressive multiple sclerosis: final report of the Northeast Cooperative Multiple Sclerosis Treatment Group. Neurology 1993; 43: 910-918.
10. Bornstein MB, Miller A, Slagle S et al. A placebo-controlled, double-blind, randomized, two center, pilot trial of Cop 1 in chronic progressive multiple sclerosis. Neurology 1991; 41: 533-539.
11. Sipe JC, Romine JS, Koziol JA et al. Cladribine in treatment of chronic progressive multiple sclerosis. Lancet 1994; 344: 9-13.
12. van Bekkum DW. BMT in experimental autoimmune diseases. Bone Marrow Transplant 1993; 11: 183-187.
13. Marmont AM. Immune ablation followed by allogeneic or autologous bone marrow transplantation: a new treatment for severe autoimmune diseases? Stem Cells 1994; 12: 125-135.
14. Marmont AM, van Bekkum DW. Stem cell transplantation for severe autoimmune diseases: new proposals but still unanswered questions. Bone Marrow Transplant 1995; 16: 497-498.
15. Burt RK, Burns W, Hess A. Bone marrow transplantation for multiple sclerosis. Bone Marrow Transplant 1995; 16: 1-6.
16. Tyndall A, Gratwohl A. Haemopoietic stem cell and progenitor cells in the treatment of severe autoimmune diseases. Ann Rheum Dis 1996; 55: 149-151.
17. van Gelder M, van Bekkum DW. Treatment of relapsing experimental autoimmune encephalomyelitis in rats with allogeneic bone marrow transplantation from a resistant strain. Bone Marrow Transplant 1995; 16: 343-351.
18. Slavin S, Karussis D, Weiss L et al. Immunohematopoietic reconstitution by allogeneic or autologous bone marrow grafts as a means for induction of specific unresponsiveness to donor-specific allografts and modified self in autoimmune disorders. Transplant Proc 1993; 25: 1274-1275.
19. Karussis DM, Vourka-Karoussis U, Lehmann D et al. Immunomodulation of autoimmunity in MRL/1pr mice with syngeneic bone marrow transplantation (SBMT). Clin Exp Immunol 1995; 100: 111-117.
20. Karussis DM, Vourka-Karoussis U, Lehmann D et al. Prevention and reversal of adoptively transferred, chronic relapsing experimental autoimmune encephalomyelitis with a single high dose cytoreductive treatment followed by syngeneic bone marrow transplantation. J Clin Invest 1993; 92: 765-772.
21. van Gelder M, Kinwell-Bohre EPM, van Bekkum DW. Treatment of experimental allergic encephalomyelitis in rats with total body irradiation and syngeneic BMT. Bone Marrow Transplant 1993; 11: 233-241.
22. van Gelder M, van Bekkum DW. Effective treatment of relapsing experimental autoimmune encephalomyelitis with pseudoautologous bone marrow transplantation. Bone Marrow Transplant 1996; 18: 1029-1034.
23. Liu Yin JA, Jowitt SN. Resolution of immune-mediated diseases following allogeneic bone marrow transplantation for leukaemia. Bone Marrow Transplant 1992; 9: 31-33.
24. Lowenthal RM, Cohen ML, Atkinson K, Biggs JC. Apparent cure of rheumatoid arthritis by bone marrow transplantation. J Rheumatol 1993; 20: 137-140.
25. van Bekkum DW, Marmont AM, Tyndall A et al. Severe autoimmune diseases: a new target for bone marrow transplantation. Stem Cells 1996; 14: 460-472.
26. Euler HH, Marmont AM, Bacigalupo A et al. Early recurrence or persistence of autoimmune diseases after unmanipulated autologous stem cell transplantation. Blood 1996; 88: 3621-3625.
27. Tyndall A, Black C, Finke J et al. Treatment of systemic sclerosis with autologous haemopoietic stem cell transplantation. Lancet 1997; 349: 254.
28. Snowden JA, Hannah EE, O'Donnell J et al. Resolution of longstanding lupus erythematosus (SLE) after autologous bone marrow transplantation for non-Hodgkin's lymphoma: a case report. Bone Marrow Transplant 1996; 17 (Suppl. 1): 6 (Abstr. 70).
29. Poser CM, Paty DW, Scheinberg L et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983; 13: 227-231.
30. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983; 33: 1444-1452.
31. Sipe JC, Knobler L, Braheny SL et al. A neurologic rating scale (NRS) for use in multiple sclerosis. Neurology 1984; 34: 1368-1372.
32. Rapp NS, Gilroy J, Lerner AM. Role of bacterial infection in exacerbation of multiple sclerosis. Am J Phys Med Rehabil 1995; 74: 415-418.
33. Patzold U, Pocklington PR. Course of multiple sclerosis: first results of a prospective study carried out on 102 MS patients from 1976-80. Acta Neurol Scand 1982; 65: 248-266.
34. Ebers GC. Treatment of multiple sclerosis. Lancet 1994; 343: 275-279.
35. Copelan EA, Deeg HJ. Conditioning for allogeneic marrow transplantation in patients with lymphohematopoietic malignancies without the use of total body irradiation. Blood 1992; 80: 1648-1658.
36. Burt RK, Hess A, Burns W et al. Syngeneic bone marrow transplantation eliminates autoreactive V β8.2 T lymphocytes from the spinal cord of Lewis rats with experimental allergic encephalomyelitis. J Neurosci Res 1995; 41: 526-531.
37. van Besien K, Demuynck H, Lemaistre CF et al. High-dose melphalan allows durable engraftment of allogeneic bone marrow. Bone Marrow Transplant 1995; 15: 321-323.
38. Kaplan RS, Wiernik PH. Neurotoxicity of antitumor agents. In: Perry MC, Yarbro JW (eds). Toxicity of Chemotherapy. Grune & Stratton: Orlando, 1984, pp 365-431.
39. Burgue F, Maraninchi D, Olive D et al. Incidence and characterization of residual host lymphocytes after various conditioning regimens to bone marrow transplantation. Bone Marrow Transplant 1988; 3 (Suppl. 1). 199-200.
40. Powles RL, Milliken S, Helenglass G et al. The use of melphalan in conjunction with total body irradiation as treatment for acute leukaemia. Transplant Proc 1989; 21: 2955-2957.
41. Gassmann W, Uharek L, Erbersdobler A et al. High-dose cytostatic agents in allogeneic bone marrow transplantation: comparison of the engraftment promoting potential. Br J Haematol 1991; 78: 310-318.
42. Grau JM, Casademont J, Monforte R et al. Myasthenia gravis after allogeneic bone marrow transplantation: report of a new case and pathogenic considerations. Bone Marrow Transplant 1990; 5: 435-437.
43. Aldouri MA, Ruggier R, Epstein O, Prentice HG. Adoptive transfer of hyperthyroidism and autoimmune thyroiditis following allogeneic bone marrow transplantation for chronic myeloid leukaemia. Br J Haematol 1990; 74: 118-119.
44. Vialettes B, Maraninchi D, San Marco MP et al. Autoimmune polyendocrine failure - type I (insulin-dependent) diabetes mellitus and hypothyroidism - after allogeneic bone marrow transplantation in a patient with lymphoblastic leukaemia. Diabetologia 1993; 36: 541-546.
45. Moreau T, Thorpe J, Miller D et al. Preliminary evidence from magnetic resonance imaging for reduction in disease activity after lymphocyte depletion in multiple sclerosis. Lancet 1994; 344: 298-301.
46. Weinshenker BG, Bass B, Karlik S et al. An open trial of OKT3 in patients with multiple sclerosis. Neurology 1991; 41: 1047-1052.
47. Lindsey JW, Hodgkinson S, Mehta R et al. Phase 1 clinical trial of chimeric monoclonal anti-CD4 antibody in multiple sclerosis. Neurology 1994; 44: 413-419.
48. Goodkin DE, Rudick RA, Van der Brug-Medendorp S et al. Low-dose (7.5 mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis. Ann Neurol 1995; 37: 30-40.
49. Karussis DM, Meiner Z, Lehmann D et al. Treatment of secondary progressive multiple sclerosis with the immunomodulator linomide: a double blind, placebo-controlled pilot study with monthly magnetic resonance imaging evaluation. Neurology 1996; 47: 341-346.
50. Kolb HJ, Guenther W, Duell T et al for the IBMTR and EBMT/EULEP Study Group on Late Effects. Cancer after bone marrow transplantation. Bone Marrow Transplant 1992; 10 (Suppl. 1): 135-138.